0001493152-16-013223.txt : 20160909 0001493152-16-013223.hdr.sgml : 20160909 20160909161020 ACCESSION NUMBER: 0001493152-16-013223 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160909 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20160909 DATE AS OF CHANGE: 20160909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PetLife Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001354591 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 331133537 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52445 FILM NUMBER: 161878940 BUSINESS ADDRESS: STREET 1: 433 N. CAMDEN DR. CITY: BEVERLY HILLS STATE: CA ZIP: 90210 BUSINESS PHONE: (310) 279-5152 MAIL ADDRESS: STREET 1: 433 N. CAMDEN DR. CITY: BEVERLY HILLS STATE: CA ZIP: 90210 FORMER COMPANY: FORMER CONFORMED NAME: ECO VENTURES GROUP, INC. DATE OF NAME CHANGE: 20110602 FORMER COMPANY: FORMER CONFORMED NAME: Modern Renewable Technologies, Inc. DATE OF NAME CHANGE: 20100114 FORMER COMPANY: FORMER CONFORMED NAME: Vault Technology, Inc. DATE OF NAME CHANGE: 20080507 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported):

September 9, 2016 (September 9, 2016)

PetLife Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Nevada

000-52445

33-1133537

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

38 West Main Street, Hancock, MD 21750		90210
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (844) 473-8543

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into Material Definitive Agreement

On July 20, 2016, Petlife Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with its wholly-owned subsidiary, PetLife Merger Subsidiary, Inc., a Nevada Corporation, with PetLife Merger Subsidiary, Inc. being the surviving entity. As part of that merger, the name of the Petlife Merger Subsidiary was changed back to PetLife Pharmaceuticals, Inc. The purpose of the subsidiary merger was to effectuate a 1 for 5 reverse exchange of Petlife’s common stock pursuant to the terms of the merger. The combined entities continue on public markets pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended.

That corporate action has been reviewed by the Financial Industry Regulatory Authority (“FINRA”) and they have advised that the action will be effectuated on public markets on Monday, September 12, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PETLIFE PHARMACEUTICALS, INC.

(Registrant)

Dated: September 9, 2016	By:	/s/ Ralph T. Salvagno, MD
		Ralph T. Salvagno, MD
		Chief Executive Officer